Crinetics Pharmaceuticals (CRNX) Receivables - Other (2017 - 2026)

Crinetics Pharmaceuticals' Receivables - Other history runs 9 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 23.97% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $9.0 million (up 23.97% YoY), while the FY2025 annual figure was $7.8 million, down 6.64% from the prior year.
• Receivables - Other for Q1 2026 stood at $9.0 million, up from $7.8 million in the prior quarter.
• The five-year high for Receivables - Other was $9.0 million in Q1 2026, with the low at $90000.0 in Q4 2023.
• The 5-year median for Receivables - Other is $2.6 million (2023), against an average of $3.6 million.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other slumped 93.35% in 2023, then surged 9133.33% in 2024.
• Crinetics Pharmaceuticals' Receivables - Other stood at $1.4 million in 2022, then plunged by 93.35% to $90000.0 in 2023, then soared by 9133.33% to $8.3 million in 2024, then fell by 6.64% to $7.8 million in 2025, then gained by 15.46% to $9.0 million in 2026.
• Business Quant data shows CRNX's Receivables - Other at $9.0 million in Q1 2026, $7.8 million in Q4 2025, and $6.3 million in Q3 2025.